The FDA has issued a nonapprovable letter to Allergan for tazarotene capsules (oral tazarotene) for the treatment of psoriasis.
Nonapprovable letter to Allergan
The FDA has issued a nonapprovable letter to Allergan for
tazarotene capsules.
The FDA has issued a nonapprovable letter to Allergan for
tazarotene capsules.
The FDA has issued a nonapprovable letter to Allergan for tazarotene capsules (oral tazarotene) for the treatment of psoriasis.
Get the most out of
Register for free and enjoy unlimited access to: